Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide versus placebo for renal outcomes in type 2 diabetes and chronic kidney disease
2018-002878-50Phase 3Unknown
- Sponsor
- Novo Nordisk
- Start
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Semaglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Composite renal and cardiovascular outcome. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2018-002878-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002878-50.